Devillier et al. has also showed a negative impact on survival of the ASXL1 mutation in AML‐MRC patients,16 but in our series, patients with MDS history are not significantly affected by ASXL1 mutation. The gene discussed is ASXL1; the disease is myelodysplastic syndrome.